Filed pursuant to Rule 424(b)(3)
Registration No.: 333-270353
PROSPECTUS SUPPLEMENT No. 2
(To the Prospectus dated June 1, 2023)
BIODEXA PHARMACEUTICALS PLC
8,203,200 Ordinary Shares Representing 20,508
American Depositary Shares
This prospectus supplement
No. 2 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Post-Effective Amendment No. 2
to Registration Statement on Form F-1, effective as of June 1, 2023 (the “Prospectus”), related to the resale by the selling
shareholders identified in the Prospectus of up to an aggregate of 8,203,200 of our ordinary shares, nominal value £0.02 per share,
represented by 20,508 American Depositary Shares (the “Depositary Shares”).
This Prospectus Supplement
is being filed in order to incorporate into and include in the Prospectus the information contained in our attached Form 6-K, filed with
the Securities and Exchange Commission on July 24, 2023.
This Prospectus Supplement
should be read in conjunction with the Prospectus and is qualified by reference to the Prospectus except to the extent that the information
in this Prospectus Supplement supersedes the information contained therein.
Our Depositary Shares are
listed on the NASDAQ Capital Market under the symbol “BDRX.” The last reported closing price of Depositary Shares on the NASDAQ
Capital Market on July 21, 2023 was $5.60.
Investing in our securities
involves risks. See “Risk Factors” beginning on page 11 of the Prospectus and in the documents incorporated by reference in
the Prospectus for a discussion of the factors you should carefully consider before deciding to purchase these securities.
Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus
is truthful or complete. Any representation to the contrary is a criminal offense.
______________________________
The date of this Prospectus Supplement is July
24, 2023.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of July 2023
Commission File Number: 001-37652
Biodexa Pharmaceuticals PLC
(Translation of registrant's name into English)
1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ] Form 40-F [ ]
This Report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the Company’s Registration Statements on Form F-3 (File No. 333-233901) and Form F-1 (File No. 333-240984).
SUBMITTED HEREWITH
Attached to the Registrant’s Form 6-K filing for the month of July 2023 is:
Exhibit No. | | Description |
| | |
99.1 | | Press Release dated July 24, 2023 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | Biodexa Pharmaceuticals PLC |
| | (Registrant) |
| | |
| | |
Date: July 24, 2023 | | /s/ Stephen Stamp |
| | Stephen Stamp |
| | Chief Executive Officer, Chief Financial Officer |
| | |
Exhibit 99.1
Biodexa
Regain Compliance with NASDAQ Minimum Bid Price Requiremen
Biodexa Pharmaceuticals PLC
(“Biodexa” or the “Company”)
Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement
Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical company developing a pipeline
of products aimed at primary and metastatic cancers of the brain, announced today that, on July 20, 2023, it received a notification
from The Nasdaq Stock Market LLC (“Nasdaq”) confirming the Company has cured the previously disclosed bid price deficiency,
and that the Company is in compliance with all applicable listing standards.
The Company’s securities will continue to be listed and traded on Nasdaq
and the previously announced hearing with the Nasdaq Hearing Panel is cancelled.
Nasdaq further notified the Company that it will
be subject to a Mandatory Panel Monitor for a period of one year from July 20, 2023. If, within that one-year monitoring period, the
Listing Qualifications Staff finds the Company out of compliance with the rules that was subject to the previous exception, the Staff
will issue a delisting determination letter and the Company will have the opportunity to request a hearing with the Nasdaq Hearings Panel.
Biodexa
Pharmaceuticals PLC |
Stephen
Stamp, CEO, CFO |
Tel:
+44 (0)29 2048 0180 |
www.biodexapharma.com |
|
Edison
Group (US Investor Relations) Alyssa Factor Tel: +1 (860) 573 9637 Email:
afactor@edisongroup.com | |
About
Biodexa Pharmaceuticals PLC
Biodexa
Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company
developing a pipeline of products aimed at primary and metastatic cancers of the brain.
The Company’s lead candidate, MTX110, is being studied in aggressive rare/orphan brain
cancer indications including recurrent glioblastoma and diffuse midline glioma.
MTX110
is a liquid formulation of the histone deacetylase (HDAC) inhibitor, panobinostat.
This proprietary formulation enables delivery of the product via convection-enhanced delivery
(CED) at potentially chemotherapeutic doses directly to the site of the tumour, by-passing
the blood-brain barrier and avoiding systemic toxicity.
Biodexa
is supported by three proprietary drug delivery technologies focused on improving the bio-delivery
and bio-distribution of medicines. Biodexa’s headquarters and R&D facility
is in Cardiff, UK. For more information visit www.biodexapharma.com.
Forward-Looking
Statements
Certain
statements in this announcement may constitute “forward-looking statements” within
the meaning of legislation in the United Kingdom and/or United States. Such statements
are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995 and are based on management’s belief or interpretation. All statements
contained in this announcement that do not relate to matters of historical fact should be
considered forward-looking statements.
Reference
should be made to those documents that Biodexa shall file from time to time or announcements
that may be made by Biodexa in accordance with the rules and regulations promulgated by the
SEC, which contain and identify other important factors that could cause actual results to
differ materially from those contained in any projections or forward-looking statements.
These forward-looking statements speak only as of the date of this announcement. All
subsequent written and oral forward-looking statements by or concerning Biodexa are expressly
qualified in their entirety by the cautionary statements above. Except as may be required
under relevant laws in the United States, Biodexa does not undertake any obligation to publicly
update or revise any forward-looking statements because of new information, future events
or events otherwise arising.
Midatech Pharma (NASDAQ:MTP)
Historical Stock Chart
From Apr 2024 to May 2024
Midatech Pharma (NASDAQ:MTP)
Historical Stock Chart
From May 2023 to May 2024